Alpha 2.0
Login Register
» Authors » Maxime K Drabo

Maxime K Drabo

Explore the profile of Maxime K Drabo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 97
Followers 0
Related Specialties
Tropical Medicine
General Medicine
Science
Top 10 Co-Authors
Halidou Tinto
Innocent Valea
Lieven Huybregts
Umberto DAlessandro
Zekiba Tarnagda
Isidore Traore
Robert T Guiguemde
Arnaud Eric Diendere
Marc Christian Tahita
Toussaint Rouamba
Published In
Malar J
PLoS One
Acta Trop
Ther Clin Risk Manag
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
Rouamba T, Ouedraogo E, Barry H, Yameogo N, Sondo A, Boly R, et al.
Int J Infect Dis . 2022 Mar; 118:224-229. PMID: 35227869
Objectives: Our study aimed to assess the statistical relationship between the use of chloroquine phosphate or hydroxychloroquine plus azithromycin (CQ/HCQ + AZ) and virological recovery, disease worsening, and death among...
2.
Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
Rouamba T, Barry H, Ouedraogo E, Tahita M, Yameogo N, Poda A, et al.
Ther Clin Risk Manag . 2021 Nov; 17:1187-1198. PMID: 34815671
Introduction: Though chloroquine derivatives are used in the treatment of coronavirus disease 2019 (COVID-19) in many countries worldwide, doubts remain about the safety and efficacy of these drugs, especially in...
3.
Dengue virus infection and pregnancy outcomes during the 2017 outbreak in Ouagadougou, Burkina Faso: A retrospective cohort study
Tougma S, ZoungranaYameogo W, Dahourou D, SalouKagone I, Compaore T, Kabore A, et al.
PLoS One . 2020 Sep; 15(9):e0238431. PMID: 32886677
Introduction: Dengue fever is a re-emerging pathology in Burkina Faso. It affects everyone and pregnant women are not left out. The objective of this study was to estimate the burden...
4.
Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso
Bonkoungou I, Aliabadi N, Leshem E, Kam M, Nezien D, Drabo M, et al.
Vaccine . 2018 Jan; 36(47):7170-7178. PMID: 29290478
Background: Burkina Faso was one of the first African nations to introduce pentavalent rotavirus vaccine (RV5, RotaTeq) into its national immunization program in October 2013. We describe the impact and...
5.
Malaria related care-seeking-behaviour and expenditures in urban settings: A household survey in Ouagadougou, Burkina Faso
Beogo I, Huang N, Drabo M, Ye Y
Acta Trop . 2016 May; 160:78-85. PMID: 27154586
In Sub-Sahara Africa, malaria inflicts a high healthcare expenditure to individuals. However, little is known about healthcare expenditure to individual affected by malaria and determinants of healthcare seeking behaviour in...
6.
Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes
Valea I, Tinto H, Drabo M, Huybregts L, Henry M, Roberfroid D, et al.
Malar J . 2014 Mar; 9:324. PMID: 24576068
Background: Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) is being implemented in most malaria endemic countries as a standard two-doses regimen as it reduces the risk of low birth weight (LBW)...
7.
An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso
Valea I, Tinto H, Drabo M, Huybregts L, Sorgho H, Ouedraogo J, et al.
Malar J . 2012 Mar; 11:71. PMID: 22433778
Background: A prospective study aiming at assessing the effect of adding a third dose sulphadoxine-pyrimethamine (SP) to the standard two-dose intermittent preventive treatment for pregnant women was carried out in...